Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bryant ranch prepack - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsules should not be used in patients with a known hypersensitivity to the drug.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - flucytosine (unii: d83282dt06) (flucytosine - unii:d83282dt06) - flucytosine capsules are indicated only in the treatment of serious infections caused by susceptible strains of candida and/or cryptococcus . candida: septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. limited trials in pulmonary infections justify the use of flucytosine. cryptococcus: meningitis and pulmonary infections have been treated effectively. studies in septicemias and urinary tract infections are limited, but good responses have been reported. flucytosine capsules should be used in combination with amphotericin b for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to flucytosine capsules (see microbiology ). flucytosine capsule is contraindicated in patients with a known hypersensitivity to the drug. flucytosine capsule is contraindicated in patients with known complete dihydropyrimidine dehydrogenase (dpd) enzyme deficiency (see warnings ).

Irland - Englisch - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - famciclovir - film-coated tablet - 250 milligram(s) - nucleosides and nucleotides excl. reverse transcriptase inhibitors; famciclovir

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

northstar rx llc - famciclovir (unii: qic03ani02) (penciclovir - unii:359hue8fjc) - famciclovir 125 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

west-ward pharmaceuticals corp. - famciclovir (unii: qic03ani02) (penciclovir - unii:359hue8fjc) - famciclovir 500 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

actavis pharma, inc. - famciclovir (unii: qic03ani02) (penciclovir - unii:359hue8fjc) - famciclovir 125 mg

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - famciclovir (unii: qic03ani02) (penciclovir - unii:359hue8fjc) - famciclovir 125 mg

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - famciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - elovax is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of the rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster is generally a milder condition in younger patients. elovax is also indicated in the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. elovax is also indicated for suppression of recurrent genital herpes. elovax is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent patients elovax is also indicated in immunocompromised patients for: treatment of uncomplicated herpes zoster; treatment of recurrent herpes simplex; suppression of recurrent herpes simplex.